Wanbury Limited specializes in the pharmaceutical sector, focusing on Active Pharmaceutical Ingredients (APIs) and formulations. It holds a significant global market share in products such as Metformin and Sertraline, establishing robust leadership in these key therapeutic categories.

The company has successfully undergone an operational and financial turnaround over the last two years, transitioning towards growth momentum and de-risked financial structures, with a notable reduction in debt levels and borrowing costs.

Wanbury has fortified its market presence with established global regulatory approvals, including USFDA and ANVISA, enhancing its credibility and access to developed markets.

Recent advances in the API business include the launch of new anaesthetic drugs and plans for 4 new molecule commercializations annually, focusing on high-value and large-volume market opportunities.

The company's business strategy emphasizes building its formulations and API brands, focusing on new therapeutic launches and geographic expansion, while deploying digital transformations for enhanced operational efficiencies.